It provides a new approach to treat myelodysplastic syndromes when decitabine comes out.In order to improve the understanding of the role of decitabine and to provide a reference for the clinical treatment of middle-risk and high-risk myelodysplastic syndromes,this article mianly summarized drug combination,prognostic molecular markers,and reviewed the mechanism of action,main medication regimen in recent 5 years for the treatment of middle-risk and high-risk myelodysplastic syndromes with decitabine.

Neurolymphomatosis is a malignant disease that occurs primary or secondary to non-Hodgkin's lymphoma and leukemia. It is mainly caused by lymphoma cells directly infiltrating peripheral nerves, and the incidence is low. The clinical manifestations vary ac-cording to the involved nerves and mainly present as decreased strength in the muscles innervated by the affected plexus/root. It is of-ten misdiagnosed as a polyneuropathy such as Guillain-Barre syndrome or chronic inflammatory demyelinating polyneuropathy. With combined treatment using immunoglobulins or steroids, the symptoms are temporarily improved but the disease still progresses rapid-ly, eventually requiring the attention of a physician. This paper will discuss clinical reports and research on neurolymphomatosis in re-cent years from the aspects of pathogenesis, clinical manifestations, differential diagnosis, diagnostic methods, treatment, and progno-sis, and will provide a theoretical basis for clinical diagnosis and treatment.